Standard BioTools Inc. Common Stock (LAB) is a publicly traded Healthcare sector company. As of May 21, 2026, LAB trades at $1.06 with a market cap of $386.11M and a P/E ratio of -5.13. LAB moved +5.00% today. Year to date, LAB is -19.70%; over the trailing twelve months it is +0.95%. Its 52-week range spans $0.87 to $2.32. Analyst consensus is neutral with an average price target of $1.35. Rallies surfaces LAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Standard BioTools Q1 revenue rises 5% to $21.1M; adjusted EBITDA loss shrinks 78%: Standard BioTools reported Q1 2026 revenue of $21.1 million, up 5% year-over-year driven by a 35% increase in consumables. It cut operating expenses 37%, reduced its adjusted EBITDA loss by 78% to $3.1 million, and closed the quarter with $524 million in cash and investments plus a $25 million earnout.
| Metric | Value |
|---|---|
| Price | $1.06 |
| Market Cap | $386.11M |
| P/E Ratio | -5.13 |
| EPS | $-0.20 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.32 |
| 52-Week Low | $0.87 |
| Volume | 1.28M |
| Avg Volume | 0 |
| Revenue (TTM) | $85.33M |
| Net Income | $-74.90M |
| Gross Margin | 49.86% |
2 analysts cover LAB: 0 strong buy, 0 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $1.35.